Puma Biotechnology Raises $60M

Los Angeles-based Puma Biotechnology, a developer of biopharmaceuticals aimed at treating cancer, said this morning that it has completed a second tranche of a $60M private financing. The company said that Leerink Swann LLC was the lead placement agent, and National Securities Corporation was the co-placement agent on the deal. Puma's shareholders include Adage Capital Partners, Brookside Capital, H&Q Healthcare Investors, H&Q Life Science Investors, and T. Rowe Price Associates. More information »